Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04618744 | A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) | PHASE2 | COMPLETED | 32 | — | — | Nov 1, 2020 | Jun 1, 2022 | Aug 6, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| ORMD-0801 (Insulin) capsule 8 mg BD | DRUG | 8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening. |
| Placebo | OTHER | Matching Placebo |